ArticleAnnals of medicine and surgery (2012)2026
FTO promotes the cervical cancer progression via regulation of FGF2 expression.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reader-dependent functional duality of FTO: a context-switching node at the intersection of immune evasion and therapeutic resistance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer remains one of the most common gynecological malignancies worldwide, with epigenetic RNA modifications playing a critical role in its development. This study aims to investigate the role of fat mass and obesity-associated protein (FTO) in cervical cancer progression and its impact on N6-methyladenosine (m6A) RNA methylation, focusing on Fibroblast Growth Factor 2 (FGF2) as a key downstream mediator. Methods: We analyzed FTO expression in adjacent normal and cervical cancer tissues by using immunohistochemistry (IHC), Western blot, and q-PCR. We also examined FTO expression and m6A modification levels in cervical cancer cell lines versus control cell lines. To investigate the impact of FTO overexpression and knockdown on cell proliferation and apoptosis, a series of functional assays, including CCK-8, flow cytometry, and immunofluorescence staining, were carried out. Furthermore, we investigated the regulation of FGF2 by FTO using the GEPIA database, qRT-PCR, and Western blot. Results: There was a notable elevation of FTO expression in cervical cancer tissues as opposed to the adjacent normal tissues. Increased levels of FTO protein and mRNA were detected in tumor tissues, along with reduced m6A modification levels of FTO mRNA. Cervical cancer cells showed higher FTO expression and decreased m6A modification compared to control cell lines. Enhanced FTO expression in HeLa cells resulted in lower global m6A levels, increased cell proliferation, and reduced apoptosis. Conversely, FTO knockdown led to reduced cell proliferation, reduced FGF2 mRNA and protein levels, diminished lactate production, and impaired cell proliferation, and increased apoptosis. Conclusion: FTO significantly influences cervical cancer progression, at least in part, through m6A modification of FGF2, thereby affecting downstream signaling. Targeting FTO and its downstream effectors holds potential as a therapeutic strategy for cervical cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.